Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports 2025

Analyst Reports 2025
May 15th 2025

Baird - New IST Data for Triple Combo Further Supportive of Potential in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

May 15th 2025

CLSA - Insightful readout; Outperform, A$0.28 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 15th 2025

Wilsons - INSIGHT-003 | Even in the arctic tumours; Maintain Overweight, A$1.05 PT(Analysts: Dr Shane Storey and Dr Lisa Worley)

May 15th 2025

Canaccord Genuity - Efti-nately worth another look; BUY, A$0.98 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 6th 2025

Bell Potter - Strong Survival Data Supports Path Forward in Head & Neck; Buy (spec.), A$0.70/sh (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

May 6th 2025

Wilsons - 17.6m OS in PD-L1 negative mHNSCC; Maintain Overweight, A$1.05 PT (Analyst: Dr Shane Storey)

May 5th 2025

Baird - Encouraging Mature OS Data for Efti+Pembro in 1L HNSCC TPS<1; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

May 5th 2025

Maxim - Positive Median Overall Survival Data for Efti + Keytruda in 1L H&N Cancer - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

May 5th 2025

Canaccord Genuity - Positive HNSCC data is a good immu-step forward; BUY, Raising PT A$0.98 (from A$0.95) (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 5th 2025

CLSA - Head & neck OS data; Retain Buy, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 5th 2025

Jefferies - Phase 2B 1L HNSCC Update – mOS Impressive; BUY, PT A$2.10 (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

May 5th 2025

Canaccord Genuity - Head and neck CPS<1 efti-cacy success; BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 2nd 2025

Canaccord Genuity - The latest updates in IO; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

April 29th 2025

Baird - Phase 3 1L NSCLC Enrollment Ongoing; Broad Development Continues; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

March 25th 2025

Maxim - P3 Study for Efti + Keytruda in 1L NSCLC Doses First Patient - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

March 25th 2025

Baird - First Patient Dosed in Phase 3 TACTI-004 for Efti Combo in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)

For a copy of this research report please contact your Baird advisor

March 4th 2025

Canaccord Genuity - 1H25 model update: All eyes on next HNSCC update; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

March 3rd 2025

Baird - Transferring Coverage: Compelling Opportunity for Efti in Phase 3 NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)

For a copy of this research report please contact your Baird advisor

February 26th 2025

Jefferies - 1HFY25: Did It Again; Buy, Raise PT to A$2.10 (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

January 24th 2025

Canaccord Genuity - TACTI-003 Cohort B musings, anticipated upcoming news flow; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor